Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$502.34M+318%$278.1M+200%$82.79M+125%-$279.86M-284%-$230.47M+30.6%
$54.81M-4.8%$55.66M-1.8%$56.32M+0.6%$56.5M+2.1%$57.56M+7.6%
$361.68M+27.6%$348.24M+28.0%$368.25M+65.6%$305.84M+27.1%$283.45M+24.8%
$714.9M+1,618%$524.08M+6,405%$265.86M-$15.54M-$47.11M
$71.56M+136%$58.7M+71.2%$44.5M+9.9%$36.55M-31.5%$30.27M-50.6%
$334.18M$473.5M$420.59M-$110.77M
-$319.51M-206%$231.59M-0.5%$311.33M+101%
$690.17M$690.16M
$643.34M+931%$465.38M+1,193%$221.36M-$52.09M-$77.38M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Alnylam Pharmaceuticals generate?
Alnylam Pharmaceuticals (ALNY) generated $714.9M in operating cash flow over the trailing twelve months.
What is Alnylam Pharmaceuticals's free cash flow?
After $71.6M of capital expenditures, Alnylam Pharmaceuticals's free cash flow was $643.3M over the trailing twelve months, up 931.4% year over year.
Where does Alnylam Pharmaceuticals's cash flow data come from?
Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.